Artiva Biotherapeutics (NASDAQ:ARTV) Posts Earnings Results, Misses Expectations By $0.24 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) issued its earnings results on Tuesday. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV traded down $0.30 on Thursday, reaching $11.40. The stock had a trading volume of 6,522 shares, compared to its average volume of 138,604. The stock’s 50-day moving average price is $12.60. Artiva Biotherapeutics has a 12-month low of $9.68 and a 12-month high of $17.31.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ARTV shares. Cantor Fitzgerald began coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 target price for the company. Jefferies Financial Group started coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday. Finally, TD Cowen began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.